Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2025 - Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants William Wood - B. Riley Securities Jack Allen - Baird Michael Okunewitch - Maxim Group Albert Lowe - Craig Hallum Capital Group Operator Welcome to the Lineage Cell Therapeutics First Quarter 2025 Conference Call.
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Jack Allen - Baird Joseph Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Mayank Mamtani - Riley Securities Albert Lowe - Craig-Hallum Sean McCutcheon - Raymond James Operator Thank you for standing by.
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.
What Makes Lineage Cell (LCTX) a New Buy Stock
Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Hsuan-Cheng Kuo - B. Riley Securities Joseph Pantginis - H.C.
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.03 per share a year ago.
